Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Unraveling new molecular players involved in the autoregulation of nodulation in Medicago truncatula.

Gautrat P, Mortier V, Laffont C, De Keyser A, Fromentin J, Frugier F, Goormachtig S.

J Exp Bot. 2019 Feb 8. doi: 10.1093/jxb/ery465. [Epub ahead of print]

PMID:
30753553
2.

MtNRLK1, a CLAVATA1-like leucine-rich repeat receptor-like kinase upregulated during nodulation in Medicago truncatula.

Laffont C, De Cuyper C, Fromentin J, Mortier V, De Keyser A, Verplancke C, Holsters M, Goormachtig S, Frugier F.

Sci Rep. 2018 Feb 1;8(1):2046. doi: 10.1038/s41598-018-20359-4.

3.

Development and validation of an HPLC-fluorescence method for the quantification of IR780-oleyl dye in lipid nanoparticles.

Varache M, Escudé M, Laffont C, Rustique E, Couffin AC.

Int J Pharm. 2017 Nov 5;532(2):779-789. doi: 10.1016/j.ijpharm.2017.06.019. Epub 2017 Jun 13.

PMID:
28619458
4.

MAP Kinase-Mediated Negative Regulation of Symbiotic Nodule Formation in Medicago truncatula.

Ryu H, Laffont C, Frugier F, Hwang I.

Mol Cells. 2017 Jan;40(1):17-23. doi: 10.14348/molcells.2017.2211. Epub 2017 Jan 31.

5.

Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, Laffont CM.

Br J Clin Pharmacol. 2017 Jul;83(7):1476-1498. doi: 10.1111/bcp.13246. Epub 2017 Mar 31.

6.

KNAT3/4/5-like class 2 KNOX transcription factors are involved in Medicago truncatula symbiotic nodule organ development.

Di Giacomo E, Laffont C, Sciarra F, Iannelli MA, Frugier F, Frugis G.

New Phytol. 2017 Jan;213(2):822-837. doi: 10.1111/nph.14146. Epub 2016 Sep 1.

7.

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, Laffont CM, Karlsson MO, Friberg LE.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):69-79. doi: 10.1007/s10928-016-9486-9. Epub 2016 Aug 30.

8.

Different Pathways Act Downstream of the CEP Peptide Receptor CRA2 to Regulate Lateral Root and Nodule Development.

Mohd-Radzman NA, Laffont C, Ivanovici A, Patel N, Reid D, Stougaard J, Frugier F, Imin N, Djordjevic MA.

Plant Physiol. 2016 Aug;171(4):2536-48. doi: 10.1104/pp.16.00113. Epub 2016 Jun 24.

9.

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF.

J Clin Pharmacol. 2016 Jul;56(7):806-15. doi: 10.1002/jcph.665. Epub 2016 Mar 11.

PMID:
26479717
10.

Flavonoids and Auxin Transport Inhibitors Rescue Symbiotic Nodulation in the Medicago truncatula Cytokinin Perception Mutant cre1.

Ng JL, Hassan S, Truong TT, Hocart CH, Laffont C, Frugier F, Mathesius U.

Plant Cell. 2015 Aug;27(8):2210-26. doi: 10.1105/tpc.15.00231. Epub 2015 Aug 7.

11.

The CRE1 cytokinin pathway is differentially recruited depending on Medicago truncatula root environments and negatively regulates resistance to a pathogen.

Laffont C, Rey T, André O, Novero M, Kazmierczak T, Debellé F, Bonfante P, Jacquet C, Frugier F.

PLoS One. 2015 Jan 6;10(1):e0116819. doi: 10.1371/journal.pone.0116819. eCollection 2015.

12.

Local and systemic regulation of plant root system architecture and symbiotic nodulation by a receptor-like kinase.

Huault E, Laffont C, Wen J, Mysore KS, Ratet P, Duc G, Frugier F.

PLoS Genet. 2014 Dec 18;10(12):e1004891. doi: 10.1371/journal.pgen.1004891. eCollection 2014 Dec.

13.

Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.

Pastor ML, Laffont CM, Gladieff L, Chatelut E, Concordet D.

Pharm Res. 2015 Feb;32(2):654-64. doi: 10.1007/s11095-014-1493-1. Epub 2014 Sep 4.

PMID:
25186439
14.

A Medicago truncatula rdr6 allele impairs transgene silencing and endogenous phased siRNA production but not development.

Bustos-Sanmamed P, Hudik E, Laffont C, Reynes C, Sallet E, Wen J, Mysore KS, Camproux AC, Hartmann C, Gouzy J, Frugier F, Crespi M, Lelandais-Brière C.

Plant Biotechnol J. 2014 Dec;12(9):1308-18. doi: 10.1111/pbi.12230. Epub 2014 Jul 24.

15.

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.

Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF.

J Clin Pharmacol. 2015 Jan;55(1):93-103. doi: 10.1002/jcph.366. Epub 2014 Jul 23.

PMID:
25043337
16.

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.

Rey JF, Laffont CM, Croubels S, De Backer P, Zemirline C, Bousquet E, Guyonnet J, Ferran AA, Bousquet-Melou A, Toutain PL.

Am J Vet Res. 2014 Feb;75(2):124-31. doi: 10.2460/ajvr.75.2.124.

PMID:
24471748
17.
18.

Bioactive cytokinins are selectively secreted by Sinorhizobium meliloti nodulating and nonnodulating strains.

Kisiala A, Laffont C, Emery RJ, Frugier F.

Mol Plant Microbe Interact. 2013 Oct;26(10):1225-31. doi: 10.1094/MPMI-02-13-0054-R.

19.

Obstetric management does not influence vertical transmission of HCV infection: results of the ALHICE group study.

Delotte J, Barjoan EM, Berrébi A, Laffont C, Benos P, Pradier C, Bongain A; ALHICE study group.

J Matern Fetal Neonatal Med. 2014 May;27(7):664-70. doi: 10.3109/14767058.2013.829813. Epub 2013 Aug 23.

PMID:
23971940
20.

Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Pastor ML, Laffont CM, Gladieff L, Schmitt A, Chatelut E, Concordet D.

Pharm Res. 2013 Nov;30(11):2795-807. doi: 10.1007/s11095-013-1099-z. Epub 2013 Jun 26.

PMID:
23801085
21.

Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology.

Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J.

J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print]

PMID:
23713757
22.

Analyzing protein distribution in plant tissues using "whole-mount" immunolocalization.

Bustos-Sanmamed P, Laffont C, Frugier F, Lelandais-Brière C, Crespi M.

Methods Mol Biol. 2013;959:317-22. doi: 10.1007/978-1-62703-221-6_21.

PMID:
23299685
23.

Analyzing small and long RNAs in plant development using non-radioactive in situ hybridization.

Bustos-Sanmamed P, Laffont C, Frugier F, Lelandais-Brière C, Crespi M.

Methods Mol Biol. 2013;959:303-16. doi: 10.1007/978-1-62703-221-6_20.

PMID:
23299684
24.

Two direct targets of cytokinin signaling regulate symbiotic nodulation in Medicago truncatula.

Ariel F, Brault-Hernandez M, Laffont C, Huault E, Brault M, Plet J, Moison M, Blanchet S, Ichanté JL, Chabaud M, Carrere S, Crespi M, Chan RL, Frugier F.

Plant Cell. 2012 Sep;24(9):3838-52. doi: 10.1105/tpc.112.103267. Epub 2012 Sep 28.

25.

Comparative transcriptomic analysis of salt adaptation in roots of contrasting Medicago truncatula genotypes.

Zahaf O, Blanchet S, de Zélicourt A, Alunni B, Plet J, Laffont C, de Lorenzo L, Imbeaud S, Ichanté JL, Diet A, Badri M, Zabalza A, González EM, Delacroix H, Gruber V, Frugier F, Crespi M.

Mol Plant. 2012 Sep;5(5):1068-81. doi: 10.1093/mp/sss009. Epub 2012 Mar 14.

26.

Dual involvement of a Medicago truncatula NAC transcription factor in root abiotic stress response and symbiotic nodule senescence.

de Zélicourt A, Diet A, Marion J, Laffont C, Ariel F, Moison M, Zahaf O, Crespi M, Gruber V, Frugier F.

Plant J. 2012 Apr;70(2):220-30. doi: 10.1111/j.1365-313X.2011.04859.x. Epub 2012 Jan 10.

27.

Characterization of a dual-affinity nitrate transporter MtNRT1.3 in the model legume Medicago truncatula.

Morère-Le Paven MC, Viau L, Hamon A, Vandecasteele C, Pellizzaro A, Bourdin C, Laffont C, Lapied B, Lepetit M, Frugier F, Legros C, Limami AM.

J Exp Bot. 2011 Nov;62(15):5595-605. doi: 10.1093/jxb/err243. Epub 2011 Aug 23.

PMID:
21862482
28.

Transcriptional and post-transcriptional regulation of a NAC1 transcription factor in Medicago truncatula roots.

D'haeseleer K, Den Herder G, Laffont C, Plet J, Mortier V, Lelandais-Brière C, De Bodt S, De Keyser A, Crespi M, Holsters M, Frugier F, Goormachtig S.

New Phytol. 2011 Aug;191(3):647-61. doi: 10.1111/j.1469-8137.2011.03719.x. Epub 2011 Apr 19.

29.

Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.

Khachman D, Conil JM, Georges B, Saivin S, Houin G, Toutain PL, Laffont CM.

J Antimicrob Chemother. 2011 Aug;66(8):1798-809. doi: 10.1093/jac/dkr220. Epub 2011 Jun 8.

PMID:
21653603
30.

Development of a complex parent-metabolite joint population pharmacokinetic model.

Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E.

AAPS J. 2011 Sep;13(3):390-404. doi: 10.1208/s12248-011-9282-9. Epub 2011 May 27.

31.

A new exact test for the evaluation of population pharmacokinetic and/or pharmacodynamic models using random projections.

Laffont CM, Concordet D.

Pharm Res. 2011 Aug;28(8):1948-62. doi: 10.1007/s11095-011-0422-9. Epub 2011 Apr 14.

PMID:
21491150
32.

A case of multifocal chronic Q fever osteomyelitis.

Acquacalda E, Montaudie H, Laffont C, Fournier PE, Pulcini C.

Infection. 2011 Apr;39(2):167-9. doi: 10.1007/s15010-010-0076-2. Epub 2011 Jan 11.

PMID:
21221701
33.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
34.

Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure.

Taylor JA, Vom Saal FS, Welshons WV, Drury B, Rottinghaus G, Hunt PA, Toutain PL, Laffont CM, VandeVoort CA.

Environ Health Perspect. 2011 Apr;119(4):422-30. doi: 10.1289/ehp.1002514. Epub 2010 Sep 20. Review. Erratum in: Environ Health Perspect. 2011 Apr;119(4):429. Toutain, Pierre-Louis [added]; Laffont, Céline M [added].

35.

The compact root architecture1 gene regulates lignification, flavonoid production, and polar auxin transport in Medicago truncatula.

Laffont C, Blanchet S, Lapierre C, Brocard L, Ratet P, Crespi M, Mathesius U, Frugier F.

Plant Physiol. 2010 Aug;153(4):1597-607. doi: 10.1104/pp.110.156620. Epub 2010 Jun 3.

36.

Outcome of exfoliative rejection after isolated intestinal transplantation in an adult: case report.

Yandza T, Schneider SM, Nishida S, Goubaux B, Badan L, Vanbiervliet G, Saint-Paul MC, Bernard G, Laffont C, Gari-Toussaint M, Girard-Pipau F, Miton V, Rahili A, Zeanandin G, Benchimol D, Tzakis A, Gugenheim J, Hébuterne X.

Transplant Proc. 2010 Jan-Feb;42(1):100-2. doi: 10.1016/j.transproceed.2009.12.023.

PMID:
20172289
37.

Evaluation of different tests based on observations for external model evaluation of population analyses.

Brendel K, Comets E, Laffont C, Mentré F.

J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):49-65. doi: 10.1007/s10928-009-9143-7. Epub 2009 Dec 23.

38.

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F.

J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):317-39. doi: 10.1007/s10928-009-9124-x. Epub 2009 Jun 27.

39.

Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera.

Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V.

J Virol Methods. 2008 Dec;154(1-2):206-9. doi: 10.1016/j.jviromet.2008.09.006. Epub 2008 Nov 7.

PMID:
18848582
40.

MicroRNA166 controls root and nodule development in Medicago truncatula.

Boualem A, Laporte P, Jovanovic M, Laffont C, Plet J, Combier JP, Niebel A, Crespi M, Frugier F.

Plant J. 2008 Jun;54(5):876-87. doi: 10.1111/j.1365-313X.2008.03448.x. Epub 2008 Feb 22.

41.

Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentré F, Lemenuel-Diot A, Girard P.

Br J Clin Pharmacol. 2007 Nov;64(5):603-12. Epub 2007 Aug 15. Review.

42.

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentré F.

Clin Pharmacokinet. 2007;46(3):221-34. Review.

43.

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Brendel K, Comets E, Laffont C, Laveille C, Mentré F.

Pharm Res. 2006 Sep;23(9):2036-49. Epub 2006 Aug 12.

44.

Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.

Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F.

J Viral Hepat. 2005 Jul;12(4):405-13.

PMID:
15985012
45.

[Hepatitis C virus infection and pregnancy].

Mariné Barjoan E, Bongain A, Laffont C, Pradier C, Dellamonica P.

Med Mal Infect. 2005 Jun;35 Suppl 2:S20-1. French. No abstract available.

PMID:
15978375
46.

Gentamicin nephrotoxicity--a comparison of in vitro findings with in vivo experiments in equines.

van der Harst MR, Bull S, Laffont CM, Klein WR.

Vet Res Commun. 2005 Apr;29(3):247-61.

PMID:
15736857
47.

Influence of fluid therapy on gentamicin pharmacokinetics in colic horses.

van der Harst MR, Bull S, Laffont CM, Klein WR.

Vet Res Commun. 2005 Feb;29(2):141-7.

PMID:
15730138
48.

Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum.

Lefrère JJ, Roudot-Thoraval F, Lunel F, Alain S, Chaix ML, Dussaix E, Gassin M, Izopet J, Pawlotsky JM, Payan C, Stoll-Keller F, Thibault V, Trabaud MA, Bettinger D, Bogard M, Branger M, Buffet-Janvresse C, Charrois A, Defer C, Laffont C, Lerable J, Levayer T, Martinot-Peignoux M, Mercier B, Rosenberg AR.

J Clin Microbiol. 2004 May;42(5):2027-30.

49.

The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C.

Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A.

J Viral Hepat. 2004 Jan;11(1):91-6.

PMID:
14738564
50.

A pharmacokinetic model to document the actual disposition of topical ivermectin in cattle.

Laffont CM, Bousquet-Mélou A, Bralet D, Alvinerie M, Fink-Gremmels J, Toutain PL.

Vet Res. 2003 Jul-Aug;34(4):445-60.

Supplemental Content

Loading ...
Support Center